PD1 cancer therapy
PD1 cancer therapy
Revolutionary Cancer Treatment: Lonza and Qurient Unite!
BIOT
🌟 Lonza's Synaffix and Qurient Therapeutics unite for dual-payload ADCs, enhancing cancer treatment with innovative cytotoxic agents! 💊🔬🚀
Revolutionary Munich Company Doses First Patient with Groundbreaking Cancer Treatment
BIOT
📢 Tubulis from Munich doses first patient with its ADC candidate TUB-040 targeting NaPi2b antigen in ovarian and lung cancer. 🧪
Breakthrough: Blockers Unveiled for Cancer Therapy’s Brain Side Effects
BIOT
🚩 German researchers find causes of CNS side effects in cancer therapy, develop blockers to protect against cognitive deficits.
